Phreesia, Inc. (0A23.L)
USD 28.5
(-1.96%)
USD 28.5
(-1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 369.84 Million USD | 6.22% |
| 2023 | 348.19 Million USD | 40.03% |
| 2022 | 248.66 Million USD | 103.88% |
| 2021 | 121.96 Million USD | 27.89% |
| 2020 | 95.36 Million USD | 31.74% |
| 2019 | 72.38 Million USD | 12.02% |
| 2018 | 64.61 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 90.74 Million USD | 2.62% |
| 2024 FY | 335.11 Million USD | -3.76% |
| 2024 Q2 | 92.48 Million USD | 1.91% |
| 2024 Q3 | 92.72 Million USD | 0.26% |
| 2024 Q4 | 84.36 Million USD | -9.02% |
| 2023 Q2 | 86.77 Million USD | -0.72% |
| 2023 FY | 348.19 Million USD | 40.03% |
| 2023 Q4 | 88.43 Million USD | 3.33% |
| 2023 Q3 | 85.58 Million USD | -1.37% |
| 2023 Q1 | 87.4 Million USD | 6.23% |
| 2022 Q1 | 40.68 Million USD | 15.24% |
| 2022 Q2 | 55.13 Million USD | 35.52% |
| 2022 Q3 | 70.56 Million USD | 27.98% |
| 2022 Q4 | 82.28 Million USD | 16.61% |
| 2022 FY | 248.66 Million USD | 103.88% |
| 2021 Q4 | 35.3 Million USD | 15.47% |
| 2021 Q3 | 30.57 Million USD | 4.35% |
| 2021 Q2 | 29.3 Million USD | 9.41% |
| 2021 FY | 121.96 Million USD | 27.89% |
| 2021 Q1 | 26.78 Million USD | 1.77% |
| 2020 Q1 | 21.61 Million USD | 9.6% |
| 2020 FY | 95.36 Million USD | 31.74% |
| 2020 Q3 | 23.78 Million USD | 0.59% |
| 2020 Q4 | 26.31 Million USD | 10.64% |
| 2020 Q2 | 23.64 Million USD | 9.37% |
| 2019 Q2 | 17.09 Million USD | 0.76% |
| 2019 Q1 | 16.96 Million USD | 0.0% |
| 2019 Q3 | 18.59 Million USD | 8.75% |
| 2019 FY | 72.38 Million USD | 12.02% |
| 2019 Q4 | 19.72 Million USD | 6.08% |
| 2018 FY | 64.61 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Accuray Incorporated | 142.61 Million USD | -159.325% |
| Align Technology, Inc. | 2.07 Billion USD | 82.192% |
| Elevance Health Inc. | 36.23 Billion USD | 98.979% |
| AxoGen, Inc. | 149.33 Million USD | -147.657% |
| Boston Scientific Corporation | 7.5 Billion USD | 95.073% |
| CVS Health Corporation | 40.68 Billion USD | 99.091% |
| Cardinal Health, Inc. | 5 Billion USD | 92.603% |
| Centene Corporation | 138.33 Billion USD | 99.733% |
| DaVita Inc. | 1.47 Billion USD | 74.909% |
| HCA Healthcare, Inc. | 45.43 Billion USD | 99.186% |
| Hologic, Inc. | 1.26 Billion USD | 70.824% |
| Humana Inc. | 102.36 Billion USD | 99.639% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 66.158% |
| Laboratory Corporation of America Holdings | 2.02 Billion USD | 81.704% |
| Masimo Corporation | 867 Million USD | 57.342% |
| McKesson Corporation | 8.67 Billion USD | 95.737% |
| Patterson Companies, Inc. | 1.12 Billion USD | 67.193% |
| Quest Diagnostics Incorporated | 1.61 Billion USD | 77.029% |
| ResMed Inc. | 1.36 Billion USD | 72.972% |
| Henry Schein, Inc. | 2.93 Billion USD | 87.408% |
| Teladoc Health, Inc. | 2.09 Billion USD | 82.312% |
| Universal Health Services, Inc. | 9.2 Billion USD | 95.984% |
| Veeva Systems Inc. | 1.25 Billion USD | 70.579% |
| Baxter International Inc. | 5.27 Billion USD | 92.985% |
| Becton, Dickinson and Company | 6.71 Billion USD | 94.49% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 87.517% |
| Danaher Corporation | 8.75 Billion USD | 95.776% |
| Stryker Corporation | 9.2 Billion USD | 95.984% |
| Medtronic plc | 16.12 Billion USD | 97.707% |